These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. Ketter TA, Post RM, Parekh PI, Worthington K. J Clin Psychiatry; 1995 Oct; 56(10):471-5. PubMed ID: 7559374 [Abstract] [Full Text] [Related]
3. Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression. Tulen JH, Volkers AC, van den Broek WW, Bruijn JA. J Clin Psychopharmacol; 2006 Oct; 26(5):542-4. PubMed ID: 16974207 [No Abstract] [Full Text] [Related]
4. MAO inhibition and antidepressant activity. Feldstein A, Hoagland H, Rivera Oktem M, Freeman H. Int J Neuropsychiatry; 1965 Aug; 1(4):384-7. PubMed ID: 5324597 [No Abstract] [Full Text] [Related]
5. Differential response patterns to MAO inhibitors and tricyclics. Nies A. J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):70-7. PubMed ID: 6376487 [Abstract] [Full Text] [Related]
6. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Quitkin FM, Stewart JW, McGrath PJ, Tricamo E, Rabkin JG, Ocepek-Welikson K, Nunes E, Harrison W, Klein DF. Br J Psychiatry Suppl; 1993 Sep; (21):30-4. PubMed ID: 8217065 [Abstract] [Full Text] [Related]
7. Depressive symptomatology and drug response. Bech P. Commun Psychopharmacol; 1978 Sep; 2(5):409-18. PubMed ID: 216525 [No Abstract] [Full Text] [Related]
8. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies. Chouinard G, Saxena BM, Nair NP, Kutcher SP, Bakish D, Bradwejn J, Kennedy SH, Sharma V, Remick RA, Kukha-Mohamad SA. Clin Neuropharmacol; 1993 Sep; 16 Suppl 2():S51-4. PubMed ID: 8313397 [Abstract] [Full Text] [Related]
10. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Ballenger JC, Post RM. Commun Psychopharmacol; 1978 Sep; 2(2):159-75. PubMed ID: 352607 [No Abstract] [Full Text] [Related]
11. Phenelzine treatment of melancholia. McGrath PJ, Stewart JW, Harrison W, Wager S, Quitkin FM. J Clin Psychiatry; 1986 Aug; 47(8):420-2. PubMed ID: 3525522 [Abstract] [Full Text] [Related]
12. Depression as a lethal disease: prevention strategies. Coppen A. J Clin Psychiatry; 1994 Apr; 55 Suppl():37-45. PubMed ID: 8077174 [Abstract] [Full Text] [Related]
13. Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant. McGrath PJ, Stewart JW, Nunes EN, Quitkin FM. J Clin Psychiatry; 1994 Aug; 55(8):336-9. PubMed ID: 8071301 [Abstract] [Full Text] [Related]
14. Phenelzine for chronic depression: a study of continuation treatment. Harrison W, Rabkin J, Stewart JW, McGrath PJ, Tricamo E, Quitkin F. J Clin Psychiatry; 1986 Jul; 47(7):346-9. PubMed ID: 3522558 [Abstract] [Full Text] [Related]
15. Limitation and potential hazards of MAOI's for the treatment of depressive symptoms in abstinent alcoholics. Schottenfeld RS, O'Malley SS, Smith L, Rounsaville BJ, Jaffe JH. Am J Drug Alcohol Abuse; 1989 Jul; 15(3):339-44. PubMed ID: 2669469 [No Abstract] [Full Text] [Related]
16. Biological relationships between mania and melancholia. Post RM, Uhde TW. Encephale; 1982 Jul; 8(2):213-28. PubMed ID: 6179764 [Abstract] [Full Text] [Related]
17. [Discussion of reports on new orientations in the treatment of affective disturbances]. Encephale; 1979 Jul; 5(5 Suppl):737-42. PubMed ID: 548282 [No Abstract] [Full Text] [Related]